HeatherAnneParsonsMDMPH

Breast Cancer, Hematologic Oncology

Dana-Farber Cancer Institute, Harvard Medical School

Dr. Parsons is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
450 Brookline Ave
Boston, MA 02215
Phone+1 617-632-1992

Fax+1 617-632-1930

Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2012 - 2015
Johns Hopkins UniversityResidency, Internal Medicine, 2009 - 2012
Drexel University College of MedicineClass of 2009

Neratinib +/- Fulvestrant in HER2+, ER+ Metastatic Breast Cancer Start of enrollment: 2017 Oct 25
Terminated
Phase 2
STOP-HER2: Stopping Trastuzumab in HER2+ MBC Start of enrollment: 2023 Apr 19
Recruiting
Phase 2
Roles: Principal Investigator, Contact

PubMed

Patient-reported outcomes, and perceptions and knowledge about recurrence in women with hormone receptor-positive breast cancer.
Shoshana M Rosenberg, Yue Zheng, Katheryn Santos, Elizabeth Riley, Hugh Wallace Meadows
Breast Cancer Research and Treatment. 2025-02-01
Clonal Hematopoiesis in Women With Breast Cancer.
Christina Mayerhofer, Rachel A Freedman, Heather A Parsons, Ann H Partridge, Peter G Miller
Journal of Clinical Oncology. 2025-01-17
Factors Associated With Short- and Long-Term Survival in Metastatic HER2-Positive Breast Cancer.
José P Leone, Ruth Moges, Julieta Leone, Carlos T Vallejo, Heather A Parsons
Clinical Breast Cancer. 2025-01-08

Journal Articles

Tumor Fraction in Cell-Free DNA as a Biomarker in Prostate Cancer
Heather A. Parsons, Atish D. Choudhury, Lauren C. Harshman, Daniel G. Stover, The Journal of Clinical Investigation

Evolving Conversations in HER2+ Oligometastatic Breast Cancer ManagementSeptember 19th, 2024
STOP-HER2: Stopping Trastuzumab in HER2+ MBCFebruary 9th, 2023
Tumor DNA Assay Portends Metastatic Breast Cancer Recurrence Months in AdvanceJune 10th, 2022
Join now to see all